Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Citadel CEO criticizes Trump’s Fed attacks, warning they could have ‘steep costs.’ Here’s how to protect your portfolio

View original at finance.yahoo.com
Citadel CEO criticizes Trump’s Fed attacks, warning they could have ‘steep costs.’ Here’s how to protect your portfolio Fabrice Coffrini / Getty Images: Samuel Corum / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Multifamily investment fundamentals remain solid amid ongoing economic and interest rate uncertainty

    80% confidence

  • S&P 500 will deliver annualized returns between 3.9% to 5.9% over the next 10 years

    80% confidence

  • Inflation remains somewhat elevated

    80% confidence

  • The District of Columbia criminal investigation is unprecedented

    80% confidence

  • December 2026 gold price forecast is $5,400 per ounce, up 15% from early February spot price

    80% confidence

  • January was the most volatile month in precious metals history

    80% confidence

  • Trump's strategy of publicly criticizing the Fed, suggesting dismissal of governors and pressuring the central bank to adopt a more permissive stance toward inflation carries steep costs

    80% confidence

  • The criminal investigation charges are a result of setting interest rates based on best assessment of what will serve the public rather than aligning with political interests

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Citadel CEO criticizes Trump’s Fed attacks, warning they could have ‘steep costs.’ Here’s how to protect your portfolio — Source | Via News | Finance Via News